Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202

Oncogene

Volumn 18, Issue 3, 1999, Pages 807-811

  Yan, Duen Hwa ^a   Wen, Yong ^a   Spohn, Bill ^a   Choubey, Divaker ^a,b   Gutterman, Jordan U ^a   Hung, Mien Chie ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anchorage independent growth; Growth retardation; Interferon inducible protein; p202; PC 3; Prostate cancer

Indexed keywords

AGAR; INTERFERON; NUCLEAR PROTEIN; PHOSPHOPROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOSTASIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

CARRIER PROTEINS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; GROWTH INHIBITORS; HUMANS; INTERFERON-ALPHA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PHENOTYPE; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033590644     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1202369     Document Type: Article

References (30)

1. Balkwill FR. (1989). Lancet, 1, 1060-1063.
2. Carreno V and Mora I. (1987). Lancet, 2, 1086-1089.
3. Choubey D and Lengyel P. (1993). J. Interferon. Res., 13, 43-52.
4. Choubey D and Lengyel P. (1995). J. Biol. Chem., 270, 6134-6140.
5. Choubey D, Li S-J, Datta B, Gutterman JU and Lengyel P. (1996a). EMBO J., 15, 5668-5678.
6. Choubey D and Gutterman JU. (1996b). Biochem. Biophys. Res. Commun., 221, 396-401.
7. Choubey D and Gutterman JU. (1997). Oncogene, 15, 291-301.
8. Datta B, Li B, Choubey D, Nallur G and Lengyel P. (1996). J. Biol. Chem., 271, 27544-27555.
9. Datta B, Min W, Burma S and Lengyel P. (1998). Mol. Cell. Biol., 18, 1074-1083.
10. Dawson MJ, Trapani JA, Briggs RC, Nicholl JK, Sutherland GR and Baker E. (1995). Immnogenetics, 41, 40-43.
11. De Young KL, Ray ME, Su YA, Anzick SL, Johnstone RW, Trapani JA, Melzer PS and Trent JM. (1997). Oncogene, 15, 453-457.
12. Fidler IJ, Heicappell R, Saiki I, Grutter MG, Horisberger MA and Nuesch J. (1987). Cancer Res., 47, 2020-2027.
13. Figlin RA, Pierce WC and Belldegrun A. (1993). Semin. Oncol., 20, 11-15.
14. Fraker DL and Alexander HR. (1994). Melanoma Res., 4 (Suppl 1), 27-29.
15. Hansen MB, Nielson SE and Berg K. (1989). J. Immunol. Methods, 119, 203-210.
16. Kaighn ME, Shankar N, Ohnuki Y, Lechner JF and Jones LW. (1979). Invest. Urol., 17, 16-23.
17. Lembo D, Angeretti A, Benefazio S, Hertel L, Gariglio M, Novelli F and Landolfo S. (1995). J. Biol. Regul. Homeost. Agents, 9, 42-46.
18. Lembo M, Sacchi C, Zappador C, Bellomo G, Gaboli M, Pandolfi PP, Gariglio M and Landolfo S. (1998). Oncogene, 16, 1543-1551.
19. Lengyel P, Choubey D, Li S-J and Datta B. (1995). Seminar in Virology, 6, 203-213.
20. Min W, Ghosh S and Lengyel P. (1996). Mol. Cell. Biol., 16, 359-368.
21. Pestka S, Langer JA, Zoon KC and Samuel CE. (1987). Annu. Rev. Biochem., 56, 727-777.
22. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP and White DE. (1988). N. Engl. J. Med., 319, 1676-1680.
23. Sen GC and Lengyel P. (1992). J. Biol. Chem., 267, 5017-5020.
24. Sica G, Fabbroni L, Castagnetta L, Cacciatore M and Pavone-Macaluso M. (1989). Urol. Res., 17, 111-115.
25. Sokoloff MH, Tso C-L, Kaboo R, Taneja S, Pang S, deKernion JB and Belldegrun AS. (1996). Cancer, 77, 1862-1872.
26. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF. (1978). Int. J. Cancer, 21, 274-281.
27. Trapani JA, Dawson M, Apostolidis VA and Browne KA. (1994). Immunogenetics, 40, 415-424.
28. van Moorselaar RJ, van Stratum P, Borm G, Debruyne FM and Sehalken JA. (1991). Prostate, 18, 331-344.
29. Von Eschenbach A, Ho R, Murphy GP, Cunningham M and Lins N. (1997). CA Cancer J. Clin., 47, 261-264.
30. Yu D, Wolf JK, Scanlon M, Price JE and Hung M-C. (1993). Cancer Res., 53, 891-898.